Table 1
From the following article
No way out for small public firms?
Peter Mitchell
Nature Biotechnology 26, 484 - 485 (2008)
doi:10.1038/nbt0508-484b
Table 1. Takeovers of public & private biotech firms, 2005–2007
| Year | Public firms (total $ value/number) | Private firms (total $ value/number) |
|---|---|---|
aExcludes AstraZeneca/MedImmune event. | ||
Data sources: Lehman Brothers, BioCentury | ||
| 2005 | 8.6 billion/14 | 3.8 billion/62 |
| 2006 | 23.5 billion/14 | 2.6 billion/59 |
| 2007 | 23.1 billion/15a | 8.7 billion/59 |